Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Atezolizumab safety study in advanced urinary tract carcinoma
NL-OMON50098Phase 3Active, not recruiting
- Sponsor
- Roche
- Start
- May 2017
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of atezolizumab in transitional cell carcinoma (TCC) and non-urothelial carcinoma of the urinary tract, sponsored by Roche. Primary endpoints: Adverse events and Safety assessments. Started May 2017; status: active, not recruiting.
02
Drugs
atezolizumab
03
Conditions
transitional cell carcinoma (TCC)non-urothelial carcinoma of the urinary tract
Beyond the preview
Go deeper on NL-OMON50098.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON50098.